All samples·Sample analysis
Get your own pass — $199
granted.bioAll samples
Analysis

radioligand therapy for prostate cancer

Overview
  • Dashboard
Analysis
  • What Surprised Us
  • Field Maturity
  • Funding Landscape
  • Competitive Topology
  • White Space
  • Market Context
Data
  • Projects115
  • Clinical Trials500
  • Patents29
  • Publications646
  • Organizations52
  • Researchers125
Reference
  • Methodology
Back
radioligand therapy for prostate cancerOrganizationsWASHINGTON UNIVERSITY

WASHINGTON UNIVERSITY

Projects attributed to WASHINGTON UNIVERSITY within this analysis sample.

In This Analysis
Projects
5
NIH Funding
$4.1M
Projects(5)
ProjectPICategoryFunding
Molecular Biomarkers of Long-Term Response to Androgen Deprivation Therapy and Radiation in Prostate Cancer
5R01CA260066-05
MAHER, CHRISTOPHER ATherapeutics$1.8M
Precision next-generation radioimmunotherapies to Cure Non-Hodgkin Lymphoma
R01CA289487
WAHL, RICHARD LEO (contact)Therapeutics$642K
Clinical Translation of the First Meitner-Auger PET Theranostic
R01CA311209
THOREK, DANIEL LYNDON JAFFEDiagnostics$641K
COMBINATION HIGH-LET MOLECULAR RADIOTHERAPY OF RELAPSED REFRACTORY NEUROBLASTOMA
5R01CA285959-02
ZHANG, HANWENTherapeutics$637K
The Radium-223 Combination Therapy Space; Improving Response and Clarifying Toxicities
R01CA240711
MICHALSKI, JEFF M.Therapeutics$414K
See WASHINGTON UNIVERSITY’s full platform profile
Cross-source view across the entire granted.bio dataset — projects, trials, patents, and publications spanning every topic, not just this analysis.